Related Experiment Video
Updated: Oct 30, 2025
Author Spotlight: Enhanced Method for Evaluating Analgesic Effects — Dual Hind Paw Carrageenan Injection in Mice
Published on: November 15, 2024
Exploration of Analgesia with Tramadol in the Coxsackievirus B3 Myocarditis Mouse Model
Sandra Pinkert1,2, Meike Kespohl1, Nicolas Kelm1,3
1Institute of Biochemistry, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany.
Abstract:
Infection of mice with Coxsackievirus B3 (CVB3) triggers inflammation of the heart and this mouse model is commonly used to investigate underlying mechanisms and therapeutic aspects for viral myocarditis. Virus-triggered cytotoxicity and the activity of infiltrating immune cells contribute to cardiac tissue injury. In addition to cardiac manifestation, CVB3 causes cell death and inflammation in the pancreas. The resulting pancreatitis represents a severe burden and under such experimental conditions, analgesics may be supportive to improve the animals' well-being. Notably, several known mechanisms exist by which analgesics can interfere with the immune system and thereby compromise the feasibility of the model. We set up a study aiming to improve animal welfare while ensuring model integrity and investigated how tramadol, an opioid, affects virus-induced pathogenicity and immune response in the heart. Tramadol was administered seven days prior to a CVB3 infection in C57BL/6 mice and treatment was continued until the day of analysis. Tramadol had no effect on the virus titer or viral pathogenicity in the heart tissue and the inflammatory response, a hallmark of myocardial injury, was maintained. Our results show that tramadol exerts no disruptive effects on the CVB3 myocarditis mouse model and, therefore, the demonstrated protocol should be considered as a general analgesic strategy for CVB3 infection.
Insights
Tramadol, an opioid analgesic, can be safely used in Coxsackievirus B3 (CVB3) infected mice. This study found tramadol does not disrupt the viral myocarditis mouse model, ensuring animal welfare without compromising research integrity.
Area of Science:
- Virology
- Immunology
- Cardiology
- Pharmacology
Background:
- Coxsackievirus B3 (CVB3) infection in mice is a key model for studying viral myocarditis, characterized by cardiac inflammation and injury.
- CVB3 also induces pancreatitis, necessitating analgesics for animal welfare, but these can potentially interfere with immune responses and model validity.
- Investigating the impact of analgesics like tramadol is crucial for maintaining the integrity of CVB3-induced myocarditis research.
Purpose of the Study:
- To evaluate the effect of tramadol administration on viral pathogenicity and immune response in a CVB3-induced myocarditis mouse model.
- To determine if tramadol compromises the feasibility of the CVB3 myocarditis model, ensuring animal welfare while preserving research integrity.
Main Methods:
- C57BL/6 mice were administered tramadol seven days prior to CVB3 infection and continued until analysis.
- Viral titers, cardiac pathogenicity, and inflammatory responses in the heart tissue were assessed.
- The study compared outcomes in tramadol-treated and untreated CVB3-infected mice.
Main Results:
- Tramadol administration did not affect viral titers in the heart tissue.
- Tramadol did not alter viral pathogenicity or the inflammatory response indicative of myocardial injury.
- The integrity of the CVB3 myocarditis mouse model was maintained in tramadol-treated animals.
Conclusions:
- Tramadol can be used as an analgesic in the CVB3-induced myocarditis mouse model without disrupting key pathological and immunological parameters.
- The findings support the use of tramadol as a supportive analgesic strategy to improve animal welfare in CVB3 infection studies.
- This protocol ensures model integrity, facilitating reliable research into viral myocarditis mechanisms and therapeutics.
